Clinical Trial of Vinblastine in Dogs with Transitional Cell Carcinoma of the Urinary Bladder

Journal of Veterinary Internal Medicine

Volumn 25, Issue 6, 2011, Pages 1385-1390

  Arnold, E J ^a   Childress, M O ^a   Fourez, L M ^a   Tan, K M ^a   Stewart, J C ^a   Bonney, P L ^a   Knapp, D W ^b  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

Author keywords

Cancer; Canine; Chemotherapy; Oncology

Indexed keywords

ANTINEOPLASTIC AGENT; VINBLASTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; MALE; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; URINARY BLADDER NEOPLASMS; VINBLASTINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 81355147163     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00796.x     Document Type: Article

References (22)

1. Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed. Philadelphia, PA: WB Saunders; 2007: 649-659.
2. Poirier VJ, Forrest LJ, Adams WM, et al. Piroxicam, mitoxantrone, and course fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: A pilot study. J Am Anim Hosp Assoc 2004;40:131-136.
3. Henry CJ, McCaw DL, Turnquist SE. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
4. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
5. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
6. Park J, Park S, Song C, et al. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy. Urology 2007;70:257-262.
7. Roberts JT, von der Maase H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann of Oncol 2006;17:118-122.
8. Blumenreich MS, Yagoda A, Natale RB, et al. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 1982;50:435-438.
9. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor - 41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.
10. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581-587.
11. Davies DR, Wyatt KM, Jardine JE, et al. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004;40:124-130.
12. Dhawan D, Ramos-Vara JA, Stewart JC, et al. Canine invasive transitional cell carcinoma cell lines: In vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urol Oncol 2009;27:284-92.
13. Knobloch A, Mohring SA, Eberle N, et al. Drug residues in serum of dogs receiving anticancer chemotherapy. J Vet Intern Med 2010;24:379-383.
14. Friedman LM, Furburg CD, DeMets DL. eds. Fundamentals of Clinical Trials, 3rd ed. St Louis, MO: Mosby; 1996.
15. Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Δ (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc 2008;233:921-924.
16. Veterinary Co-Operative Oncology Group. Veterinary co-operative oncology group - Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
17. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
18. Mutsaers AJ, Widmer WR, Knapp DW, et al. Canine transitional cell carcinoma. J Vet Intern Med 2003;17:136-144.
19. Knapp DW, Glickman NW, DeNicola DB, et al. Naturally-occurring canine transitional cell carcinoma of the urinary bladder: A relevant model of human invasive bladder cancer. Urol Onc 2000;5:47-59.
20. Bailey DB, Rassnick KM, Kristal O, et al. Phase 1 dose escalation of single-agent vinblastine in dogs. J Vet Intern Med 2008;22:1397-1402.
21. Vickery KR, Wilson H, Vail DM, et al. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet Comp Oncol 2008;6:111-119.
22. Price GS, Frazier DL. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. J Vet Intern Med 1998;12:267-271.